Format

Send to

Choose Destination
Urology. 2007 Aug;70(2):217-20.

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Author information

1
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Abstract

OBJECTIVES:

To investigate the association between a cytochrome P450 17alpha-hydroxylase gene (CYP17) polymorphism and survival in Caucasian patients with androgen-independent prostate cancer (AIPC).

METHODS:

The study used 222 samples acquired from Caucasian patients with AIPC. The CYP17 polymorphism (-34T>C) was analyzed using polymerase chain reaction amplification followed by restriction fragment length polymorphism detection.

RESULTS:

No significant differences were observed in the frequencies of the CYP17 genotype in relation to categorized Gleason scores, age at diagnosis, or hormone therapy. The median survival was significantly longer in 126 patients with the CYP17 A2 allele (8.9 years) genotype than in 96 patients with the A1 allele (6.7 years) genotype (P = 0.040 by log-rank test). Similarly, the estimated survival probability at 10 years (24% in A1 allele versus 43% in A2 allele) showed a statistically significant difference between the two groups (P = 0.002 by the permutation test).

CONCLUSIONS:

These results suggest that the CYP17 polymorphism is associated with overall survival in patients with AIPC.

PMID:
17826473
PMCID:
PMC1994899
DOI:
10.1016/j.urology.2007.06.1097
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center